Company Filing History:
Years Active: 2022-2023
Title: Innovations of Zhuotun Zhu in Medical Imaging
Introduction
Zhuotun Zhu is a notable inventor based in Bethesda, MD (US), recognized for his contributions to the field of medical imaging. He holds two patents that showcase his innovative approaches to enhancing computer-aided diagnosis and image segmentation.
Latest Patents
Zhu's latest patents include a "Device and method for detecting clinically important objects in medical images with distance-based decision stratification." This method involves acquiring a medical image set and generating a three-dimensional (3D) tumor distance map. Each voxel in the tumor distance map represents the distance from the voxel to the nearest boundary of a primary tumor. The method also includes performing neural-network processing to generate a predicted probability map for the presence and locations of oncology significant lymph nodes (OSLNs) in the medical image set.
Another significant patent is the "Method and device for stratified image segmentation." This method entails obtaining a 3D image data set that represents a region with at least three levels of objects. It generates segmentation results indicating boundaries of anchor-level, mid-level, and small-level objects based on various neural network models.
Career Highlights
Zhuotun Zhu is currently employed at Ping An Technology (Shenzhen) Co., Ltd., where he continues to develop innovative solutions in medical imaging. His work focuses on improving diagnostic accuracy and efficiency through advanced imaging techniques.
Collaborations
Zhu has collaborated with notable colleagues, including Dakai Jin and Adam Patrick Harrison, contributing to a dynamic research environment that fosters innovation.
Conclusion
Zhuotun Zhu's work in medical imaging exemplifies the intersection of technology and healthcare, showcasing his commitment to advancing diagnostic methods. His patents reflect significant advancements that have the potential to improve patient outcomes in medical diagnostics.